Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Peterson

Neurological Surgery Miami, FL Medical Doctor

NPI 1801900436 CMS profile 217494

1475 Nw 12Th Ave, Miami, FL 33136

Open in the dashboard

General payments

$10,127,874

301 records reported · program years 2019–2025

Research payments

$4,875

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Peterson of Miami, FL is reported in the CMS Open Payments database as having received $10,127,874 across 301 general payments and $4,875 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $423 15
2024 General $1,151,625 17
2023 General $2,687,277 21
2022 General $1,530,713 68
2021 General $1,177,898 67
2021 Research $875 2
2020 General $3,505,640 32
2020 Research $4,000 1
2019 General $74,298 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Peterson
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Eric Peterson were reported at $423. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Eric Peterson Neurological Surgery median Middle half National median
2019 $74,298 $582 $138–$3,006 $163
2020 $3,505,640 $294 $76–$2,174 $114
2021 $1,177,898 $387 $105–$2,432 $132
2022 $1,530,713 $542 $139–$2,989 $149
2023 $2,687,277 $534 $145–$2,697 $160
2024 $1,151,625 $574 $155–$3,046 $164
2025 $423 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $6,544,927 119 payments
  2. Medtronic USA, Inc. $3,510,132 35 payments
  3. Stryker Corporation $39,175 35 payments
  4. Penumbra, Inc. $13,315 33 payments
  5. Medical Device Business Services, Inc. $9,578 7 payments
  6. DePuy Synthes Products, Inc. $4,378 1 payment
  7. Terumo Medical Corporation $4,000 2 payments
  8. AbbVie, Inc. $643 23 payments
  9. Lilly USA, LLC $518 5 payments
  10. Allergan Inc. $253 12 payments
  11. Other $955 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Acquisitions $6,474,803 6 payments
  2. Royalty or License $3,481,349 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $88,395 23 payments
  4. Consulting Fee $52,148 11 payments
  5. Travel and Lodging $22,585 124 payments
  6. Food and Beverage $8,595 136 payments
Products named General payments · program years 2019–2025
  1. RIST $5,364,345 61 payments
  2. Rist-5F Catheters $3,481,349 1 payment
  3. Rist-5F Catheters $1,177,076 51 payments
  4. Pipeline $21,451 11 payments
  5. CATALYST $17,885 6 payments
  6. FLOWGATE $15,580 6 payments
  7. ATLAS $13,593 5 payments
  8. TREVO $13,357 6 payments
  9. EMBOTRAP II Revascularization Device $8,548 5 payments
  10. DAC $6,277 4 payments
  11. Other $50,893 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic USA, Inc. $4,000 1 payment
  2. Medtronic, Inc. $875 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Neurosurgery: 83

Drug cost

$37

Median for Neurosurgery: $872

Branded share of claims

100%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 12 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$39,212

Medicare's payments for the services billed

Medicare patients

44

Average age 71

Services billed

171

25 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 36%
Ischemic heart disease 32%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $172
$172 — —
TREMFYA
  • Janssen Biotech, Inc. $137
$137 — —
TALTZ
  • Lilly USA, LLC $58
$58 — —
MOUNJARO
  • Lilly USA, LLC $30
$30 — —
ZEPBOUND
  • Lilly USA, LLC $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

304 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record